[HTML][HTML] Guidelines for the diagnosis and treatment of hepatocellular carcinoma (2019 edition)
J Zhou, H Sun, Z Wang, W Cong, J Wang, M Zeng… - Liver cancer, 2020 - karger.com
Background: Primary liver cancer, around 90% are hepatocellular carcinoma in China, is the
fourth most common malignancy and the second leading cause of tumor-related death …
fourth most common malignancy and the second leading cause of tumor-related death …
[HTML][HTML] Positron-emission tomography for hepatocellular carcinoma: Current status and future prospects
RC Lu, B She, WT Gao, YH Ji, DD Xu… - World journal of …, 2019 - ncbi.nlm.nih.gov
Hepatocellular carcinoma (HCC) is one of the leading causes of cancer mortality worldwide.
Various imaging modalities provide important information about HCC for its clinical …
Various imaging modalities provide important information about HCC for its clinical …
2019 Update of Indian national association for study of the liver consensus on prevention, diagnosis, and management of hepatocellular carcinoma in India: the puri II …
A Kumar, SK Acharya, SP Singh, A Arora… - Journal of clinical and …, 2020 - Elsevier
Hepatocellular carcinoma (HCC) is one of the major causes of morbidity, mortality, and
healthcare expenditure in patients with chronic liver disease in India. The Indian National …
healthcare expenditure in patients with chronic liver disease in India. The Indian National …
[HTML][HTML] Atezolizumab plus bevacizumab followed by curative conversion (ABC conversion) in patients with unresectable, TACE-unsuitable intermediate-stage …
M Kudo - Liver cancer, 2022 - karger.com
Atezolizumab plus bevacizumab (Atezo/Bev) followed by curative conversion (ABC
conversion) therapy is very effective in the treatment of unresectable, transarterial …
conversion) therapy is very effective in the treatment of unresectable, transarterial …
Guidelines for the diagnosis and treatment of primary liver cancer (2022 edition)
J Zhou, H Sun, Z Wang, W Cong, M Zeng, W Zhou… - Liver Cancer, 2023 - karger.com
Background: Primary liver cancer, of which around 75–85% is hepatocellular carcinoma in
China, is the fourth most common malignancy and the second leading cause of tumor …
China, is the fourth most common malignancy and the second leading cause of tumor …
[HTML][HTML] 18F-FDG PET/CT radiomic analysis for classifying and predicting microvascular invasion in hepatocellular carcinoma and intrahepatic cholangiocarcinoma
Background Microvascular invasion (MVI) is a critical risk factor for early recurrence of
hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (ICC). The aim of this …
hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (ICC). The aim of this …
PET-based radiogenomics supports mTOR pathway targeting for hepatocellular carcinoma
Purpose: This work aimed to explore in depth the genomic and molecular underpinnings of
hepatocellular carcinoma (HCC) with increased 2 [18F] fluoro-2-deoxy-d-glucose (FDG) …
hepatocellular carcinoma (HCC) with increased 2 [18F] fluoro-2-deoxy-d-glucose (FDG) …
Evidence of prostate-specific membrane antigen expression in hepatocellular carcinoma using 68Ga-PSMA PET/CT
S Kuyumcu, D Has-Simsek, R Iliaz, Y Sanli… - Clinical nuclear …, 2019 - journals.lww.com
Materials and Methods Nineteen HCC patients who underwent 18 F-fluorodeoxyglucose (18
F-FDG) positron emission tomography (PET) as part of restaging procedure also underwent …
F-FDG) positron emission tomography (PET) as part of restaging procedure also underwent …
[HTML][HTML] The critical role of glucose deprivation in epithelial-mesenchymal transition in hepatocellular carcinoma under hypoxia
H Jo, J Lee, J Jeon, SY Kim, J Chung, H Ko, M Lee… - Scientific reports, 2020 - nature.com
Imaging with 18F-fluorodeoxyglucose (FDG) positron emission tomography/computed
tomography (PET/CT) is used to determine sites of abnormal glucose metabolism to predict …
tomography (PET/CT) is used to determine sites of abnormal glucose metabolism to predict …
[HTML][HTML] Potentials of Non-Invasive 18F-FDG PET/CT in Immunotherapy Prediction for Non–Small Cell Lung Cancer
X Liao, M Liu, R Wang, J Zhang - Frontiers in Genetics, 2022 - frontiersin.org
The immune checkpoint inhibitors (ICIs), by targeting cytotoxic-T-lymphocyte-associated
protein 4, programmed cell death 1 (PD-1), or PD-ligand 1, have dramatically changed the …
protein 4, programmed cell death 1 (PD-1), or PD-ligand 1, have dramatically changed the …